SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HuMAB companies
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (568)11/4/2003 11:34:48 AM
From: Icebrg  Read Replies (1) of 1022
 
NovImmune’s pipeline for Therapeutic Monoclonal Antibodies

Pipeline Development Strategy

* NovImmune’s current pipeline consists of 10 different monoclonal programmes at various stages of discovery and development, all focused in the field of immune-related disorders and inflammation

* NovImmune’s pipeline will be a mixture of 100% internally funded drug candidates and 50/50 co-development profit sharing candidates

* To continue to acquire proprietary targets from biotechnology companies and academic laboratories

* First two products ready for preclinical and clinical development.

The first two therapeutic monoclonal antibodies selected by NovImmune as its first two drugs have been fully validated in terms of medical relevance in the very large medical field of autoimmune diseases and inflammation. They will therefore both be moved into preclinical and clinical development with no regulatory or safety toxicology roadblocks, and with a high likelihood of positive clinical outcome.

The unique feature of the first two NovImmune drugs is that they are the fully human versions of humanised therapeutic monoclonal antibodies that have already been fully validated, not only in animal models of human diseases, but also in Phase I and Phase II clinical trials in Psoriasis and Type I Diabetes. In addition, they are currently being evaluated in Inflammatory Bowel Disease and Rheumatoid Arthritis.

NI-0401 and NI-0501:

* Into GMP production fall 2003
* IND filing and clinical development late 2004

novimmune.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News